Business, energy, technology, markets and global industry news from Business News Today

Series B funding

Pharma & Biotech

Can Kinaset’s inhaled JAK inhibitor finally bring relief to all severe asthma patients?

Kinaset raises $103M to advance frevecitinib, a novel inhaled JAK inhibitor for severe asthma. Find out what makes this candidate different.

Read More